Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Assessment of Skeletal Muscle Alterations and Circulating Myokines in MASLD Patients: A Prospective Cohort Study

Version 1 : Received: 21 June 2024 / Approved: 22 June 2024 / Online: 24 June 2024 (12:00:52 CEST)

How to cite: Real Martínez, Y.; Fernandez-Garcia, C. E.; González-Rodríguez, A.; Fuertes-Yebra, E.; Calvo Soto, M.; Berlana, A.; Barrios, V.; Caldas, M.; González Moreno, L.; García-Buey, L. C.; Molina Baena, B.; Sampedro Nuñez, M.; Beceiro, M. J.; García-Monzón, C. Assessment of Skeletal Muscle Alterations and Circulating Myokines in MASLD Patients: A Prospective Cohort Study. Preprints 2024, 2024061598. https://doi.org/10.20944/preprints202406.1598.v1 Real Martínez, Y.; Fernandez-Garcia, C. E.; González-Rodríguez, A.; Fuertes-Yebra, E.; Calvo Soto, M.; Berlana, A.; Barrios, V.; Caldas, M.; González Moreno, L.; García-Buey, L. C.; Molina Baena, B.; Sampedro Nuñez, M.; Beceiro, M. J.; García-Monzón, C. Assessment of Skeletal Muscle Alterations and Circulating Myokines in MASLD Patients: A Prospective Cohort Study. Preprints 2024, 2024061598. https://doi.org/10.20944/preprints202406.1598.v1

Abstract

Aim: To determine the prevalence of skeletal muscle alterations (SMA) in patients with meta-bolic dysfunction-associated steatotic liver disease (MASLD) and to assess the significance of circulating myokines as potential biomarkers of SMA in patients with MASLD. Material and methods: Measurements of both skeletal muscle strength and skeletal muscle mass parameters, anthropometric and metabolic features as well as serum levels of different myokines were per-formed in a cohort of 62 MASLD patients and then compared according to the stage of liver fi-brosis and hepatosteatosis degree both diagnosed by transitional elastography. Results: No sig-nificant differences were found in skeletal muscle strength and skeletal muscle mass in MASLD patients stratified according to the stage of liver fibrosis. Noteworthy, serum levels of FGF21 were significantly higher in MASLD patients with advanced hepatic fibrosis (F3-F4) than in those with lower stages of hepatic fibrosis (F0-F2) (197.49±198.27 pg/ml vs 95.62±83.67 pg/ml, p=0.049, respectively). MASLD patients with severe hepatosteatosis (S3) had significantly higher serum levels of irisin (1116.87±1161.86 pg/ml) than those with lower grades (S1-S2) (385.21±375.98 pg/ml, p=0.001). Conclusion: SMA were uncommon in our MASLD patients, particularly in those with lower stages of liver fibrosis. An increase in serum FGF21 was detected in patients with a higher stage of fibrosis with possible therapeutic implications in MASLD.

Keywords

skeletal muscle; myokines; MASLD; liver fibrosis; hepatosteatosis.

Subject

Medicine and Pharmacology, Gastroenterology and Hepatology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.